隶属于 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2009
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Baird Medical successfully launched its minimally invasive Microwave Ablation (MWA) technology at Bakersfield Memorial Hospital in California, marking the first ablation case for benign thyroid tumors in the San Joaquin Valley region. - The company secured regulatory approvals from Pakistan's Medical Device Board and Vietnam's Ministry of Health, expanding its compliant footprint in Southeast Asian markets. - Dr. Tim Beck performed the inaugural procedure at Bakersfield Memorial, demonstrating the system's high-efficiency ablation capabilities and favorable safety profile in a high-volume hospital setting. - These strategic deployments reinforce Baird Medical's position as a market leader in MWA technology, with solutions now used in over 30 prestigious US hospitals including Mayo Clinic and Columbia University Medical Center.
- Vaccinex announced a $60 million revenue sharing agreement with Pepinemab Development Venture to fund an enlarged Phase 2b clinical trial of pepinemab for Alzheimer's disease treatment. - The anti-SEMA4D antibody pepinemab demonstrated promising results in early trials, blocking harmful brain inflammation and preserving vascular integrity while reducing disease-related proteins in cerebrospinal fluid. - Recent genetic research identified the SEMA4D-PLXNB1 signaling pathway as a key regulator of Ast10 astrocytes, which correlate with cognitive decline in Alzheimer's patients. - Pepinemab treatment reduced Ast10 cell representation in the brain and appeared to slow cognitive decline compared to placebo controls in previous studies.
- A study published in Open Forum Infectious Diseases demonstrates that earlier use of Delve Bio's metagenomic next-generation sequencing (mNGS) test could reduce diagnostic testing by up to 92% and shorten time to diagnosis by over 10 days for certain patient populations. - The comprehensive mNGS testing technology, available through Delve Detect, can identify RNA and DNA pathogens within 48 hours and provides 22% greater diagnostic yield compared to traditional methods. - Real-world data shows the test could eliminate hundreds of unnecessary tests and reduce hospital stays for patients with meningitis/encephalitis, offering significant cost savings at both patient and institutional levels.
- XmAb30819, a novel 2+1 bispecific T-cell engager targeting ENPP3 and CD3, demonstrates initial antitumor activity in patients with advanced clear cell renal cell carcinoma in an ongoing phase 1 trial. - The agent selectively targets ENPP3, a protein highly expressed in 93% of clear cell RCC tumors but minimally present in normal tissues, offering a promising new mechanism of action. - Preliminary safety data shows manageable cytokine release syndrome with treatment durations exceeding one year in several patients, supporting continued dose escalation. - The development addresses a critical unmet need for patients with RCC who have progressed on standard VEGF inhibitors and immunotherapy combinations.
- New research reveals that exercising once or twice a week as a "weekend warrior" provides similar cognitive health benefits as more frequent physical activity, potentially reducing mild cognitive impairment risk by 25%. - A large-scale study following over 10,000 participants for 16 years found that both weekend warriors and regularly active individuals had significantly lower rates of cognitive decline compared to non-exercisers. - Scientists estimate approximately 13% of mild cognitive impairment cases could be prevented if all middle-aged adults engaged in at least one or two weekly exercise sessions.
- Research published in the journal Heart reveals that individuals who walk at a brisk pace (over 4 mph) have a 43% lower risk of developing abnormal heart rhythms compared to slower walkers. - The study of nearly 421,000 participants found that brisk walking specifically reduced atrial fibrillation risk by 46%, with researchers attributing approximately 36% of the protective effect to reduced inflammation and improved metabolism. - Scientists from the University of Glasgow conclude that faster walking pace should be emphasized in physical activity recommendations as a potential strategy for preventing cardiac arrhythmias.
- Adolescents who achieve the recommended 9-11 hours of sleep nightly demonstrate a 37% lower risk of developing high blood pressure compared to their sleep-deprived peers. - Teens with both insomnia and insufficient sleep (less than 7.7 hours) face a fivefold increased risk of hypertension, highlighting the critical relationship between sleep quality and cardiovascular health. - Researchers emphasize the importance of early intervention in sleep habits, as poor sleep patterns established during adolescence often persist into adulthood and may contribute to lifelong cardiovascular risks.
- Baird Medical has received regulatory approval from Indonesia's Ministry of Health for its Great Wall Microwave Therapeutic Instrument and Disposable Microwave Ablation Needle, marking a significant expansion into Southeast Asia. - The company's microwave ablation technology offers a minimally invasive procedure for treating thyroid nodules and tumors, providing precision treatment with faster recovery times and minimal impact on surrounding tissues. - As an FDA 510(k)-certified medical device company, Baird Medical plans to leverage this approval to establish distribution networks and partnerships with key Indonesian medical institutions, furthering its presence in emerging markets.
- The 'Young, Empowered & Strong' (YES) study is a multicenter, randomized controlled trial evaluating a mobile app- and web-based intervention for young breast cancer survivors. - YES aims to improve quality of life and address specific concerns and symptoms experienced by adolescent and young adult (AYA) breast cancer patients. - The intervention utilizes electronic patient-reported outcome systems (ePROs) to provide tailored education and resources based on individual needs. - The study will assess the efficacy of YES at 6 months and sustainability at 9 months, with potential for broad application to AYA survivors of other cancers.
- A double-blind, placebo-controlled study found that cannabigerol (CBG) significantly reduced overall feelings of anxiety in cannabis users. - Participants reported no intoxication or significant side effects, and CBG did not impair cognitive or motor functions. - Surprisingly, CBG enhanced verbal memory at 45- and 60-minute check-ins, a finding that warrants further investigation. - The study provides initial scientific evidence supporting the anecdotal use of CBG for anxiety relief, distinguishing it from THC's effects.
